Healthcare provider profile · identity verified

James A. Nitahara, MD

Internal Medicine · PANORAMA CITY, CA · NPI 1124176177

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	1009	334
Amlodipine Besylate	Amlodipine Besylate	771	253
Lisinopril	Lisinopril	532	176
Metformin Hcl	Metformin Hcl	368	124
Losartan Potassium	Losartan Potassium	332	111
Rosuvastatin Calcium	Rosuvastatin Calcium	327	110
Atenolol	Atenolol	320	100
Simvastatin	Simvastatin	302	92
Levothyroxine Sodium	Levothyroxine Sodium	300	88
Omeprazole	Omeprazole	272	113
Jardiance	Empagliflozin	246	78
Glipizide	Glipizide	239	78
Terazosin Hcl	Terazosin Hcl	221	84
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	198	24
Albuterol Sulfate Hfa	Albuterol Sulfate	184	67
Hydrochlorothiazide	Hydrochlorothiazide	176	55
Alendronate Sodium	Alendronate Sodium	157	52
Fluticasone Propionate	Fluticasone Propionate	148	60
Metformin Hcl Er	Metformin Hcl	139	51
Gabapentin	Gabapentin	132	53
Allopurinol	Allopurinol	107	43
Potassium Chloride	Potassium Chloride	106	38
Trazodone Hcl	Trazodone Hcl	105	32
Sertraline Hcl	Sertraline Hcl	102	45
Famotidine	Famotidine	95	47
Pantoprazole Sodium	Pantoprazole Sodium	89	30
Fluoxetine Hcl	Fluoxetine Hcl	88	32
Carvedilol	Carvedilol	87	24
Ezetimibe	Ezetimibe	87	34
Pradaxa	Dabigatran Etexilate Mesylate	85	27
Tamsulosin Hcl	Tamsulosin Hcl	80	28
Hydralazine Hcl	Hydralazine Hcl	77	28
Metoprolol Tartrate	Metoprolol Tartrate	77	26
Pravastatin Sodium	Pravastatin Sodium	74	24
Triamcinolone Acetonide	Triamcinolone Acetonide	73	43
Alvesco	Ciclesonide	71	39
Finasteride	Finasteride	71	24
Hydrocortisone	Hydrocortisone	66	27
Humulin N	Insulin Nph Human Isophane	65	21
Clopidogrel	Clopidogrel Bisulfate	63	24
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	54	17
Ozempic	Semaglutide	54	12
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	50	24
Lorazepam	Lorazepam	49	17
Glimepiride	Glimepiride	45	22
Fenofibrate	Fenofibrate	44	13
Amoxicillin	Amoxicillin	43	37
Furosemide	Furosemide	42	22
Acetaminophen-Codeine	Acetaminophen With Codeine	41	suppressed
Nitroglycerin	Nitroglycerin	40	31
Mirtazapine	Mirtazapine	38	11
Meloxicam	Meloxicam	35	15
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	35	17
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	34	34
Isosorbide Mononitrate Er	Isosorbide Mononitrate	32	13
Warfarin Sodium	Warfarin Sodium	32	12
Cephalexin	Cephalexin	30	26
Citalopram Hbr	Citalopram Hydrobromide	30	11
Colchicine	Colchicine	30	18
Eliquis	Apixaban	30	11
Spiriva Respimat	Tiotropium Bromide	30	suppressed
Acyclovir	Acyclovir	29	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	29	29
Ibuprofen	Ibuprofen	27	15
Benazepril Hcl	Benazepril Hcl	25	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	24	suppressed
Betamethasone Dipropionate	Betamethasone Dipropionate	23	suppressed
Morphine Sulfate Er	Morphine Sulfate	23	suppressed
Victoza 2-Pak	Liraglutide	23	suppressed
Xarelto	Rivaroxaban	23	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	22	suppressed
Duloxetine Hcl	Duloxetine Hcl	22	suppressed
Prednisone	Prednisone	22	20
Wixela Inhub	Fluticasone Propion/Salmeterol	22	13
Humulin N Kwikpen	Insulin Nph Human Isophane	21	suppressed
Metoprolol Succinate	Metoprolol Succinate	21	suppressed
Propranolol Hcl	Propranolol Hcl	21	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	21	suppressed
Clobetasol Propionate	Clobetasol Propionate	20	11
Spironolactone	Spironolactone	20	suppressed
Azelastine Hcl	Azelastine Hcl	19	suppressed
Paroxetine Hcl	Paroxetine Hcl	19	suppressed
Digoxin	Digoxin	18	suppressed
Levetiracetam	Levetiracetam	18	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	17	suppressed
Fluocinonide	Fluocinonide	17	suppressed
Humulin R	Insulin Regular, Human	17	suppressed
Lamotrigine	Lamotrigine	17	suppressed
Liraglutide	Liraglutide	16	suppressed
Ondansetron Odt	Ondansetron	16	suppressed
Sitagliptin	Sitagliptin	16	12
Tradjenta	Linagliptin	16	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	15	15
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	15	suppressed
Temazepam	Temazepam	15	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	15	suppressed
Ciclopirox	Ciclopirox	14	suppressed
Felodipine Er	Felodipine	14	suppressed
Methocarbamol	Methocarbamol	14	suppressed
Montelukast Sodium	Montelukast Sodium	14	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	14	13
Sumatriptan Succinate	Sumatriptan Succinate	14	suppressed
Aripiprazole	Aripiprazole	13	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	13	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	12	suppressed
Clonazepam	Clonazepam	12	suppressed
Clonidine Hcl	Clonidine Hcl	12	suppressed
Desmopressin Acetate	Desmopressin (Nonrefrigerated)	12	suppressed
Januvia	Sitagliptin Phosphate	12	suppressed
Tramadol Hcl	Tramadol Hcl	12	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	12	suppressed
Valproic Acid	Valproic Acid (As Sodium Salt)	12	suppressed
Alprazolam	Alprazolam	11	suppressed
Bupropion Hcl	Bupropion Hcl	11	suppressed
Buspirone Hcl	Buspirone Hcl	11	suppressed
Ketoconazole	Ketoconazole	11	suppressed
Neomycin-Polymyxin-Dexameth	Neomycin/Polymyxin B/Dexametha	11	suppressed
Ropinirole Hcl	Ropinirole Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error